Why caffeine has been standard care for decades
For more than 20 years, caffeine has been one of the most commonly prescribed medications in neonatal intensive care units. It is used to treat and prevent apnea of prematurity — brief pauses in breathing that are common in babies born very early.
The landmark Caffeine for Apnea of Prematurity (CAP) trial, published in the New England Journal of Medicine, showed that caffeine improved short-term respiratory outcomes and longer-term neurodevelopment compared with placebo. Since then, it has become routine.
Yet one basic question remained open: which dose is best?
What changed this week
Researchers at Mercy Hospital for Women in Melbourne and the University of Melbourne have launched the BabyCCINO trial. It is designed to compare three commonly used caffeine dosing regimens in very preterm infants (born more than two months early).
The trial will enroll around 4,000 babies across Australia, New Zealand, and the United Kingdom. It is a domain within the larger PLATIPUS adaptive platform trial.
The three regimens being compared are:
Outcomes will be assessed at 42 weeks’ postmenstrual age or discharge, using an ordinal scale that captures respiratory support, survival, and other health measures. Longer-term follow-up on growth and development is planned at two to three years.
Competing viewpoints and open questions
Current practice already varies. Some units use higher doses; others stay lower. Higher doses may reduce more apnea episodes and help babies come off ventilators sooner, but they also raise questions about side effects, sleep disruption, and long-term neurodevelopment.
Earlier observational work and smaller trials have suggested benefits from higher or extended caffeine courses, including reduced intermittent hypoxia. Critics note that those studies were not large enough to settle the dose question, and that “more is better” is not always true in neonatology.
The BabyCCINO design addresses that gap by randomizing within a platform trial that can adapt as data accumulate.
What parents and clinicians should watch next
Enrollment is beginning now. The trial is not expected to report primary results for several years. In the meantime, units will continue current local protocols.
Parents of preterm infants can ask their care team which caffeine regimen is used and why. The trial does not change immediate care for babies already in the NICU.
What to watch:
This is educational background only — not medical advice. Decisions about individual babies remain with their clinical teams.
Comments (0)
No comments yet.
Sign in to comment.